Results 191 to 200 of about 316,174 (240)

Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been ...
Eugene Oh, Jessa E. Miller, Michelle J. Lee, Anna Zemke, David Baraghoshi, Matthew J. Strand, Jeremiah A. Alt, Todd E. Bodner, Michael Chang, Naweed I. Chowdhury, Patricia H. Eshaghian, Anne E. Getz, Jennifer L. Goralski, David A. Gudis, Peter H. Hwang, Ashoke Khanwalkar, Adam J. Kimple, Jivianne T. Lee, Douglas A. Li, Jess C. Mace, Jayakar V. Nayak, Jonathan B. Overdevest, Zara Patel, Daniella K. Safatian, Rodney J. Schlosser, Brent Senior, Amanda L. Stapleton, Timothy L. Smith, Zachary M. Soler, Jeffrey D. Suh, Grant A. Turner, Marilene B. Wang, Milene T. Saavedra, Jennifer L. Taylor‐Cousar, Daniel M. Beswick   +34 more
wiley   +1 more source

Lost and Found: Is Olfactory Recovery More Promising After COVID‐19 Than Other Causes, Even 2 Years Later?

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker, Mabel Berg, Nicolaus Knight, Jessica W. Grayson, Bradford A. Woodworth, Justin H. Turner, Do‐Yeon Cho   +6 more
wiley   +1 more source

When biomarkers disagree: interpreting <i>F</i>eNO and eosinophils across airway disease. [PDF]

Thorax
Almansa-López A, Romero-Palacios PJ, Alcazar Navarrete B.   +2 more
europepmc   +1 more source

Costs of Academic Engagement in Organized Plastic and Reconstructive Surgery in the United States. [PDF]

Arch Plast Surg
Shah KS, Prvulovic ST, Song DH.
europepmc   +1 more source

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. [PDF]

J Immunother Cancer
Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Stephen Hodi F, Li T, Yoder SJ, Streicher H, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA.   +11 more
europepmc   +1 more source

The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy

Annals of Neurology, EarlyView.
Objective Newborn screening (NBS) for spinal muscular atrophy (SMA) facilitates early diagnosis and treatment for affected individuals. However, fluid biomarkers that provide early insights into disease activity and outcomes in a neonatal cohort and those unable to access (due to reimbursement criteria) or deferring immediate treatment are lacking ...
Arlene D'Silva, Karen Herbert, Lakshmi Balaji, Jia Mei He, Tejaswi Kandula, Hugo A. Sampaio, Hooi‐Ling Teoh, Esther Tantsis, Jihee Sohn, Nancy Briggs, Nickson Ning, Matthew C. Kiernan, Didu S. Kariyawasam, Michelle A. Farrar   +13 more
wiley   +1 more source

Continuous Versus Short EEG After Ischemic Stroke: What cEEG Adds for Detecting Abnormalities and Predicting Post‐Stroke Epilepsy

Annals of Neurology, EarlyView.
Objective The objective of this study was to quantify incremental diagnostic yield and prognostic value of continuous electroencephalography (cEEG; ≥12 hours) versus a 60‐minute short electroencephalography (sEEG) in predicting post‐stroke epilepsy (PSE) in patients without acute symptomatic seizures.
Kai Michael Schubert, Vijaya Dasari, Chiara Tatillo, Gilles Naeije, Sándor Beniczky, Carla Bentes, Marian Galovic, Nicolas Gaspard, Vineet Punia   +8 more
wiley   +1 more source

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial. [PDF]

ESMO Open
Blaye C, Bidard FC, Hue L, Howarth K, Pierga JY, Dalenc F, Jacot W, Djerroudi L, Potonnier W, Dumas V, Lalet C, Maréchal M, Pulido M, Brunet M, Salabert L, Venat L, Maran-Gonzalez A, Saal LH, Franchet C, Birkeälv S, MacGrogan G, Bonnefoi H.   +21 more
europepmc   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Correction to: DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers. [PDF]

Strahlenther Onkol
Schnellhardt S, Böke S, Tribius S, Krause M, Haderlein M, Rühle A, Süß C, Linge A, Hecht M, Balermpas P, Head and Neck Cancer Expert Panel of the German Society of Radiation Oncology DEGRO.   +10 more
europepmc   +1 more source